Genmab AS

GMAB · Moat type: REGULIERUNG

MoatScore

6/10

Fair Value

43 USD

Margin of Safety

+32.5 %

Rating

BEOBACHTEN

Genmab is a Danish biotechnology company that generates revenue through royalties, milestone payments, and direct product sales from the development and licensing of innovative antibody therapeutics.

View full analysis →

🔒 Detailed AI analysis, peer comparison, capital allocation, crisis resilience & PDF report for Pro members.

Not investment advice. Analyses are research, not a recommendation. Valuations may be erroneous or incomplete. © MoatScan.ai — proprietary methodology.